No Data
No Data
ST Pharmaceutical (600671.SH) has received 17 pharmaceutical re-registration approval notices.
Special treat Vision Pharmaceutical (600671.SH) released an announcement, the company recently received approval and issuance from the Zhejiang Provincial Pharmaceutical Regulatory Agency...
ST Muyao (600671.SH): The controlling subsidiary plans to lease property.
On September 9, Gelonhui announced that its holding subsidiary, Qingdao Simulation Medical Technology Co., Ltd., plans to lease the Yung Jia Life Science and Technology Industrial Park A# building located at 603 Jiushui East Road, Laoshan District, Qingdao City, from Yung Jia Run Industrial Co., Ltd. The premises will be used for production, research and development, and office purposes, with a leasing area of approximately 7,862.71 square meters, for a lease term of 3 years from September 7, 2024 to September 6, 2027; the rent is payable annually, with the first year's rent being 6.3138 million yuan, the second year's rent being 6.5146 million yuan, and the third year's rent being 6.7155 million yuan.
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Hangzhou Tianmusan Pharmaceutical Co., Ltd.
ST PharM(600671.SH): The net loss in the first half of the year was 18.5007 million yuan.
On August 29th, ST Modemedicine (600671.SH) released its semi-annual report. During the reporting period, the company achieved revenue of 59.5484 million yuan, an increase of 16.87% compared to the same period last year, when the revenue was 50.9539 million yuan. The net income attributable to shareholders of the listed company was -18.5007 million yuan, a decrease of 21.01% compared to the same period last year, when the net income was -23.421 million yuan. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was -22.0571 million yuan, an increase of 4% compared to the same period last year, when the net income was -21.1039 million yuan.
ST Muyao (600671.SH): Shareholder Yuanjia Medical plans to increase its shareholding from 10 million yuan to 20 million yuan.
ST Mubodrug (600671.SH) announced that shareholder Yuanjia Medical, holding more than 5% of the company's shares, will increase its shareholding in the company within 6 months from the date of this announcement using its own funds or self-raised funds through the trading system allowed by the Shanghai Stock Exchange (including but not limited to centralized bidding, bulk trading, etc.). The amount of this shareholding increase shall not be less than 10 million RMB and not more than 20 million RMB.
No Data
No Data